Gennova Biopharmaceuticals, a subsidiary of Emcure Pharmaceuticals, is selling its mRNA business to Immunoscript Life Science for ₹139 crore. The deal allows Emcure to sharpen its focus on core biotech operations like biosimilars. The transaction is expected to be completed by July 17, 2026.
Gennova Biopharmaceuticals, the biotech subsidiary of Emcure Pharmaceuticals, has entered into a business transfer agreement to sell its mRNA-focused business unit. The division is being sold to Immunoscript Life Science Private Limited on a slump sale basis for a total consideration of ₹139 crore. The transaction is scheduled to close by July 17, 2026.
Strategic Shift to Core Biotech Focus
Emcure Pharmaceuticals has indicated that this divestment is part of a broader plan to reorganize its operations. By shedding the mRNA business, Gennova aims to dedicate its resources more effectively toward its core strengths, which include the research, development, and manufacturing of biosimilars and other biotechnology products. While the mRNA segment was notable for developing India’s first mRNA vaccine during the pandemic, its financial contribution was relatively small. The mRNA business reported revenue of ₹6.47 crore, which accounts for approximately 0.71% of Emcure's consolidated revenue of ₹911.58 crore.
Transaction and New Ownership Context
This sale is being executed as a slump sale through a business transfer agreement rather than a court-approved scheme of arrangement. The buyer, Immunoscript Life Science, is a newly incorporated entity founded in April 2026. The company is promoted by Sanjay Singh, who previously served as a director at Gennova. Immunoscript has stated that its business model will center on precision immunology, combining artificial intelligence with biological engineering and biomanufacturing to develop vaccines and advanced therapeutics.
Investor Perspective
For investors, the primary takeaway is the company's effort to streamline its portfolio by exiting a non-core, lower-contribution business segment. While the sale brings in ₹139 crore in cash, the financial impact on the consolidated top line remains limited due to the small revenue share of the divested unit. Investors may track whether the capital generated from this divestment is reinvested into the company's core biosimilar projects or used to support other financial priorities. The focus for stakeholders will now shift to the completion of the transfer by the July 17, 2026 deadline and any subsequent updates from management regarding the allocation of the proceeds.